Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review

Ibrutinib, a known Burton's tyrosine kinase (BTK) and interleukin‐2 inducible T‐cell kinase (ITK) inhibitor, is used for the treatment of B‐cell disorders (chronic lymphocytic leukemia [CLL] and various other lymphomas) and chronic graft versus host disease following allogeneic hematopoietic ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Adam Yuh, Cuttica, Michael J., Ison, Michael G., Gordon, Leo I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537222/
https://www.ncbi.nlm.nih.gov/pubmed/33043320
http://dx.doi.org/10.1002/jha2.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537222/
https://www.ncbi.nlm.nih.gov/pubmed/33043320
http://dx.doi.org/10.1002/jha2.98

Ejemplares similares